224 related articles for article (PubMed ID: 30520799)
1. Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience.
Cimminiello C; Indini A; Di Guardo L; Prisciandaro M; Randon G; Tolomio E; De Braud F; Del Vecchio M
Melanoma Res; 2019 Jun; 29(3):289-294. PubMed ID: 30520799
[TBL] [Abstract][Full Text] [Related]
2. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience.
Hribernik N; Boc M; Ocvirk J; Knez-Arbeiter J; Mesti T; Ignjatovic M; Rebersek M
Radiol Oncol; 2020 Jan; 54(1):119-127. PubMed ID: 31955148
[TBL] [Abstract][Full Text] [Related]
4. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
Cowey CL; Liu FX; Black-Shinn J; Stevinson K; Boyd M; Frytak JR; Ebbinghaus SW
J Immunother; 2018; 41(2):86-95. PubMed ID: 29252916
[TBL] [Abstract][Full Text] [Related]
6. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281
[TBL] [Abstract][Full Text] [Related]
7. Real-world experience with pembrolizumab in patients with advanced melanoma: A large retrospective observational study.
Liu FX; Ou W; Diede SJ; Whitman ED
Medicine (Baltimore); 2019 Jul; 98(30):e16542. PubMed ID: 31348273
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.
Li T; Jia DD; Teng LS
Invest New Drugs; 2020 Oct; 38(5):1334-1341. PubMed ID: 32072356
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.
Kluger HM; Chiang V; Mahajan A; Zito CR; Sznol M; Tran T; Weiss SA; Cohen JV; Yu J; Hegde U; Perrotti E; Anderson G; Ralabate A; Kluger Y; Wei W; Goldberg SB; Jilaveanu LB
J Clin Oncol; 2019 Jan; 37(1):52-60. PubMed ID: 30407895
[TBL] [Abstract][Full Text] [Related]
10. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.
Hua C; Boussemart L; Mateus C; Routier E; Boutros C; Cazenave H; Viollet R; Thomas M; Roy S; Benannoune N; Tomasic G; Soria JC; Champiat S; Texier M; Lanoy E; Robert C
JAMA Dermatol; 2016 Jan; 152(1):45-51. PubMed ID: 26501224
[TBL] [Abstract][Full Text] [Related]
11. Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab.
Durot C; Mulé S; Soyer P; Marchal A; Grange F; Hoeffel C
Eur Radiol; 2019 Jun; 29(6):3183-3191. PubMed ID: 30645669
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
[TBL] [Abstract][Full Text] [Related]
13. The use of pembrolizumab for the treatment of metastatic uveal melanoma.
Kottschade LA; McWilliams RR; Markovic SN; Block MS; Villasboas Bisneto J; Pham AQ; Esplin BL; Dronca RS
Melanoma Res; 2016 Jun; 26(3):300-3. PubMed ID: 26848796
[TBL] [Abstract][Full Text] [Related]
14. A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis.
Dagogo-Jack I; Lanfranchi M; Gainor JF; Giobbie-Hurder A; Lawrence DP; Shaw AT; Sullivan RJ
J Immunother; 2017 Apr; 40(3):108-113. PubMed ID: 28221189
[TBL] [Abstract][Full Text] [Related]
15. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
Carlino MS; Long GV; Schadendorf D; Robert C; Ribas A; Richtig E; Nyakas M; Caglevic C; Tarhini A; Blank C; Hoeller C; Bar-Sela G; Barrow C; Wolter P; Zhou H; Emancipator K; Jensen EH; Ebbinghaus S; Ibrahim N; Daud A
Eur J Cancer; 2018 Sep; 101():236-243. PubMed ID: 30096704
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Maio M; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan P; Ibrahim N; Marreaud S; van Akkooi ACJ; Suciu S; Robert C
N Engl J Med; 2018 May; 378(19):1789-1801. PubMed ID: 29658430
[TBL] [Abstract][Full Text] [Related]
17. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
Robert C; Ribas A; Hamid O; Daud A; Wolchok JD; Joshua AM; Hwu WJ; Weber JS; Gangadhar TC; Joseph RW; Dronca R; Patnaik A; Zarour H; Kefford R; Hersey P; Zhang J; Anderson J; Diede SJ; Ebbinghaus S; Hodi FS
J Clin Oncol; 2018 Jun; 36(17):1668-1674. PubMed ID: 29283791
[TBL] [Abstract][Full Text] [Related]
18. Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma.
Moser JC; Wei G; Colonna SV; Grossmann KF; Patel S; Hyngstrom JR
Acta Oncol; 2020 Apr; 59(4):434-437. PubMed ID: 31920132
[No Abstract] [Full Text] [Related]
19. Pembrolizumab as first-line treatment for metastatic uveal melanoma.
Rossi E; Pagliara MM; Orteschi D; Dosa T; Sammarco MG; Caputo CG; Petrone G; Rindi G; Zollino M; Blasi MA; Cassano A; Bria E; Tortora G; Schinzari G
Cancer Immunol Immunother; 2019 Jul; 68(7):1179-1185. PubMed ID: 31175402
[TBL] [Abstract][Full Text] [Related]
20. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
